Alkermes (ALKS) Stock Forecast & Price Target

Alkermes is viewed positively because its commercial franchise delivered a 3Q26 revenue beat at $480.1M, with proprietary product sales of $417.3M and quarter-end cash, cash equivalents and investments of $787.6M, showing both operating momentum and balance-sheet strength. The base business, led by Lumryz, Vivitrol, Aristada, and Lybalvi, appears capable of generating durable cash flows that can fund rising R&D while helping offset longer-term patent and royalty headwinds. Beyond the core portfolio, the orexin pipeline offers the largest upside through encouraging data in IH and ADHD, with management and analysts seeing potential for broader sleep-disorder labeling and multi-billion-dollar revenue potential if upcoming readouts remain positive.

Alkermes is facing a negative outlook because its royalty business and proprietary products may erode through the remainder of the decade, pressuring earnings while commercial execution remains vulnerable to competition and generic entry. The company’s orexin program is still early stage, and its efficacy and safety have not been validated in larger studies, creating meaningful clinical and regulatory risk alongside the possibility of unexpected safety signals or FDA delays. Its significant exposure to Medicaid also adds policy risk, and high R&D and SG&A spending increase the chance that ongoing operations could be strained if pipeline or injectable-business performance disappoints.